CC chemokines CCL2, CCL3, CCL4 and CCL5 are elevated in osteoporosis patients

Fatehi, Farangis; Mollahosseini, Majid; Hassanshahi, Gholamhossein; Falahati-Pour, Soudeh Khanamani; Khorramdelazad, Hossein; Ahmadi, Zahra; Karimabad, Mojgan Noroozi; Farahmand, Habib

doi:10.7555/jbr.31.20150166

Cited by 16 publications

(3 citation statements)

References 7 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In a study by Farangis et al ., the circulating chemokines were detected by ELISA immediately after blood collection according to the manufacturer's guidelines for control and osteoporosis patients. Similar to the results here, three members of CCL including CCL2 , CCL3 , as well as CCL5 were elevated in osteoporosis patients 25 , whereas the mean contents of CCL3 were (936.39 ± 204) pg/mL and (134.5 ± 4.58) pg/mL in osteoporosis patients and controls, respectively. They claimed that CCL3 , through binding to CCR1 and CCR5 , could stimulate CCL5 secretion from osteoblasts.…”

Section: Discussionsupporting

confidence: 89%

Investigation of Diagnostic Biomarkers for Osteoporosis Based on Differentially Expressed Gene Profile with QCT and mDixon‐Quant Techniques

Zhu

Guo

et al. 2021

Orthopaedic Surgery

View full text Add to dashboard Cite

Objective: To develop a comprehensive differential expression profile for osteoporosis based on two independent data sources.Methods: Using a hindlimb unloading (HLU) rat model to mimic osteoporosis syndrome in humans (animal experiments), the significant differentially expressed mRNAs in osteoporosis were analyzed using RNA-seq. The enriched GO terms as well as KEGG signaling pathways were also deeply investigated. Using clinical specimens to verify the functions of potential hub genes (biomarkers) for osteoporosis (clinical experiments), 128 suspected cases for osteoporosis from January 2019 to December 2020 were randomly selected and analyzed by quantitative computed tomography (QCT) as well as modified Dixon quantification (mDixon-Quant) techniques in the Tianjin hospital. Among these, 80 patients out of 128 suspected cases were finally diagnosed as the osteoporosis group. Meanwhile, 48 patients were selected for osteopenia group. There was no significant age and gender difference across participant subgroups. The protein levels of potential hub genes (FST, CCL3, and RAPGEF4) were determined by ELISA double antibody sandwich method for osteopenia and osteoporosis groups from peripheral blood.Result: In the RNA-seq analysis, compared with control group, a total of 803 differentially expressed mRNAs were identified, including 288 up-regulated and 515 down-regulated mRNAs. Of these, FST, CCL3, CPE, RAPGEF4, IL6, MDFI, PDZD2, and GATM were primary hub genes (biomarkers) for osteoporosis. These differentially expressed genes were significantly enriched in GO terms related to extracellular matrix process and KEGG signaling pathways including osteoclast differentiation. In the functional experiments, the protein expression level of FST, CCL3, and RAPGEF4 displayed a specific expression pattern between osteoporosis patients and control group. The protein concentration of FST was 23.63 AE 6.39 ng/mL in osteoporosis patients compared as 48.36 AE 9.12 ng/mL in osteopenia group (P < 0.01). Meanwhile, CCL3 was 1.03 AE 0.64 ng/mL in osteoporosis patients vs 0.56 AE 0.24 in osteopenia group (P < 0.01) and RAPGEF4 was 53.58 AE 11.42 ng/mL in osteoporosis patients vs 66.47 AE 13.28 ng/mL in osteopenia group (P < 0.05), respectively. Conclusion:This study has identified potential gene biomarkers (the genes with most significantly differential expression and useful for distinguishing osteoporosis from other bone disorders) and established a differential expression profile for osteoporosis, which is a valuable reference for future clinical research.

show abstract

Section: Discussionsupporting

confidence: 89%

Investigation of Diagnostic Biomarkers for Osteoporosis Based on Differentially Expressed Gene Profile with QCT and mDixon‐Quant Techniques

Zhu

Guo

et al. 2021

Orthopaedic Surgery

View full text Add to dashboard Cite

show abstract

“…Plasma RANTES has been proposed as a marker of the atherosclerotic process [ 61 ]. There is a report on the increased serum level of RANTES in osteoporotic patients [ 62 ]. It seems that the elevation of the serum RANTES concentration in the ovariectomized diabetic rats may be a compensatory reaction to strong inhibition of bone formation and an increase in bone resorption.…”

Section: Discussionmentioning

confidence: 99%

Negligible Effect of Estrogen Deficiency on Development of Skeletal Changes Induced by Type 1 Diabetes in Experimental Rat Models

Janas

Kruczek

Londzin

et al. 2020

Mediators of Inflammation

View full text Add to dashboard Cite

Although postmenopausal osteoporosis often occurs concurrently with diabetes, little is known about interactions between estrogen deficiency and hyperglycemia in the skeletal system. In the present study, the effects of estrogen deficiency on the development of biochemical, microstructural, and mechanical changes induced by streptozotocin-induced diabetes mellitus (DM) in the rat skeletal system were investigated. The experiments were carried out on nonovariectomized (NOVX) and ovariectomized (OVX) control and diabetic mature female Wistar rats. Serum levels of bone turnover markers (CTX-I and osteocalcin) and 23 cytokines, bone mass and mineralization, histomorphometric parameters, and mechanical properties of cancellous and compact bone were determined. The results were subjected to two-way ANOVA and principal component analysis (PCA). Estrogen deficiency induced osteoporotic changes, with increased bone resorption and formation, and worsening of microstructure (femoral metaphyseal BV/TV decreased by 13.0%) and mechanical properties of cancellous bone (the maximum load in the proximal tibial metaphysis decreased by 34.2%). DM in both the NOVX and OVX rats decreased bone mass, increased bone resorption and decreased bone formation, and worsened cancellous bone microarchitecture (for example, the femoral metaphyseal BV/TV decreased by 17.3% and 18.1%, respectively, in relation to the NOVX controls) and strength (the maximum load in the proximal tibial metaphysis decreased by 35.4% and 48.1%, respectively, in relation to the NOVX controls). Only in the diabetic rats, profound increases in some cytokine levels were noted. In conclusion, the changes induced by DM in female rats were only slightly intensified by estrogen deficiency. Despite similar effects on bone microstructure and strength, the influence of DM on the skeletal system was based on more profound systemic homeostasis changes than those induced by estrogen deficiency.

show abstract

“…Some of these mediators such as cytokines and chemokines have been similarly considered as potential candidates for reduction of bone density in various types of inflammatory diseases through activation of osteoclast precursors, mature osteoclasts, and recruitment of other immune cells to the bone tissue. These functions and impacts have been also fully explored ( 6 , 7 ). Bone tissue osteoclasts are the main sources of cytokines and chemokines ( 8 ).…”

Section: Introductionmentioning

confidence: 99%

Involvement of Eotaxins (CCL11, CCL24, CCL26) in Pathogenesis of Osteopenia and Osteoporosis

Ahmadi¹,

Khorramdelazad²,

Hassanshahi³

et al. 2020

ijph

View full text Add to dashboard Cite

Background: The purpose of this study was to investigate the role of eotaxin family members including C-C motif chemokine 11 (CCL11), C-C motif chemokine 24 (CCL24), and C-C motif chemokine 26 (CCL26) as the subgroups of CC-chemokine in patients affected with osteoporosis and osteopenia. Methods: Overall, 19 osteoporotic patients, 18 osteopenic individuals, and 20 healthy subjects were recruited in this study. The bone mineral density (BMD) was then measured at the lumbar spine (L1-L4) and the hip (femoral neck and total hip) using dual-energy X-ray absorptiometry for diagnosis of bone density and related disorders. Additionally, enzyme-linked immunosorbent assay (ELISA) technique was employed to measure the serum levels of CCL11, CCL24, and CCL26. Results: The circulating levels of CCL11, CCL24, and CCL26 had been increased in both groups of patients with osteopenia and osteoporosis compared to those in healthy subjects (P<0.05); while no significant difference was observed between serum levels of these chemokines in such patients. Conclusion: Eotaxins can play a role in the pathogenesis of osteoporosis and osteopenia; however, further studies are needed to clarify various roles of eotaxins in the pathophysiology of osteoporosis and osteopenia.

show abstract

CC chemokines CCL2, CCL3, CCL4 and CCL5 are elevated in osteoporosis patients

Cited by 16 publications

References 7 publications

Investigation of Diagnostic Biomarkers for Osteoporosis Based on Differentially Expressed Gene Profile with QCT and mDixon‐Quant Techniques

Investigation of Diagnostic Biomarkers for Osteoporosis Based on Differentially Expressed Gene Profile with QCT and mDixon‐Quant Techniques

Negligible Effect of Estrogen Deficiency on Development of Skeletal Changes Induced by Type 1 Diabetes in Experimental Rat Models

Involvement of Eotaxins (CCL11, CCL24, CCL26) in Pathogenesis of Osteopenia and Osteoporosis

Contact Info

Product

Resources

About